Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Medtronic
UBS
US Army
Johnson and Johnson
QuintilesIMS
Queensland Health
US Department of Justice
Deloitte

Generated: June 25, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR AGGRASTAT

« Back to Dashboard

Clinical Trials for AGGRASTAT

Trial ID Title Status Sponsor Phase Summary
NCT00251576 Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) Completed Merck Sharp & Dohme Corp. Phase 3 A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner. Z-Phase: To evaluate early treatment of patients with long term chest pain (using an approved drug for 30 days, followed by an increased dose of the drug) as compared to patients (treated with diet and 4 months placebo followed by diet and approved drug) in patients who have experienced acute chest pain or heart attack.
NCT00300833 Treating Acute MI Patients With Aggrastat on Their Way to Hospital Unknown status The Baruch Padeh Medical Center, Poriya Phase 4 Treating an AMI patient with ST elevation with Aggrastat in the ambulance on his or her way to the hospital.
NCT00383136 FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or Abciximab Completed University of Bologna Phase 4 The elective("standard of care") treatment of ST - elevation acute myocardial infarction (STEMI) currently consists of primary angioplasty with stent implantation during administration of Abciximab, a inhibitor of GP IIb/IIIa platelet receptor. Tirofiban is another potent inhibitor of GP IIb/IIIa platelet receptor with an efficacy on platelet aggregation inhibition equal to or greater than Abciximab if a high dose bolus is used, i.e. 25 microg/kg, (platelet aggregation inhibition > 90% 15 minutes after infusion). It can therefore be hypothesized that this drug can improve the results of primary angioplasty to the same extent as Abciximab. The aim of this study is to compare the efficacy, in terms of myocardial reperfusion indices, of Abciximab and high dose of Tirofiban in primary angioplasty for STEMI, both in the case of treatment before transfer and of treatment in the catheterization laboratory during the procedure. The reference hypothesis for the study objective is the equivalence or the non-inferiority of Tirofiban with respect to Abciximab.
NCT00566891 Safety of High-dose Tirofiban During Coronary Angioplasty Completed S. Anna Hospital Phase 4 This single-centre study is intended to retrospectively check the safety of high-dose bolus of tirofiban in patients who underwent percutaneous angioplasty.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for AGGRASTAT

Condition Name

Condition Name for AGGRASTAT
Intervention Trials
Coronary Artery Disease 3
Acute Myocardial Infarction 3
Myocardial Infarction 2
Unstable Angina 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for AGGRASTAT
Intervention Trials
Myocardial Infarction 7
Infarction 7
Acute Coronary Syndrome 3
Myocardial Ischemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for AGGRASTAT

Trials by Country

Trials by Country for AGGRASTAT
Location Trials
United States 8
Italy 8
Israel 1
China 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for AGGRASTAT
Location Trials
Florida 2
Georgia 1
Virginia 1
Tennessee 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for AGGRASTAT

Clinical Trial Phase

Clinical Trial Phase for AGGRASTAT
Clinical Trial Phase Trials
Phase 4 5
Phase 3 4
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for AGGRASTAT
Clinical Trial Phase Trials
Completed 6
Unknown status 2
Not yet recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for AGGRASTAT

Sponsor Name

Sponsor Name for AGGRASTAT
Sponsor Trials
Medicure 3
SCRI Development Innovations, LLC 2
Merck Sharp & Dohme Corp. 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for AGGRASTAT
Sponsor Trials
Other 10
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Mallinckrodt
Boehringer Ingelheim
Merck
Colorcon
Queensland Health
AstraZeneca
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.